ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma

 
• By Alaric DeArment
  
Relay Therapeutics presented data for RLY-4008 in cholangiocarcinoma at ESMO • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business